Delivery Order SPE2DB20D1100-SPE2DB25FE2K5
- Not listed
- The Defense Logistics Agency (DLA) awarded a delivery order to AmerisourceBergen Drug Corp on August 7, 2025, for the supply of Ocrevus 300 mg/10 mL vials with a ceiling value of $48,077.16. The contract is firm fixed price with no set-aside designation, indicating competitive award, and is scheduled for completion by August 28, 2025. AmerisourceBergen will perform the work from its corporate office in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's larger...
- The Defense Logistics Agency awarded a delivery order valued at $48,077.16 to AmerisourceBergen Drug Corp for the supply of Ocrevus 300 mg/10 ml vials. This non-set-aside, firm fixed price delivery order is scheduled for completion by September 3, 2025, and will be performed at the contractor's Conshohocken, Pennsylvania facility. Ocrevus is a specialty pharmaceutical product used in the treatment of multiple sclerosis, reflecting the critical role AmerisourceBergen plays in supplying...
- The Defense Logistics Agency awarded a delivery order valued at $24,038.58 to AmerisourceBergen Drug Corp for the supply of Ocrevus 300 mg/10 mL vials on August 18, 2025. The contract is firm fixed price with no set-aside designation and is scheduled for completion by September 9, 2025. Performance will take place at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is a child contract issued under AmerisourceBergen's larger Indefinite Delivery...
- The Defense Logistics Agency awarded a $120,192.80 delivery order to AmerisourceBergen Drug Corp on July 24, 2025, for the supply of Ocrevus 300 mg/10 mL vials. This is a firm fixed-price contract with an ultimate completion date of August 14, 2025, and will be performed at the awardee's corporate office location in Conshohocken, Pennsylvania. The contract was competitively awarded with no set-aside designation, reflecting the contractor's demonstrated capability to meet federal pharmaceutical...
- The Defense Logistics Agency (DLA) awarded a delivery order to AmerisourceBergen Drug Corp for the supply of Ocrevus 300 mg/10 ml vials with a ceiling value of $72,115.74. The contract, which was competitively awarded with no set-aside designation, carries a firm fixed price structure and is scheduled for completion by August 21, 2025. Performance will be executed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order operates under...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 20, 2025, for the supply of OCREVUS 300 mg/10 mL vials valued at $36,057.84 under a Firm Fixed Price contract type. This delivery order, which is not set-aside and was competitively awarded, is scheduled for completion by September 11, 2025, with performance taking place at AmerisourceBergen's corporate office in Conshohocken, Pennsylvania. The contract represents a child order under...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $12,019.28 to AmerisourceBergen Drug Corp for the supply of Ocrevus 300 mg/10 mL vials. This firm fixed price contract, awarded on July 23, 2025, with an ultimate completion date of August 13, 2025, represents a competitively awarded, non-set-aside procurement. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, will fulfill this order from its corporate office location....
- The Defense Logistics Agency awarded a $48,077.16 delivery order to AmerisourceBergen Drug Corp on August 18, 2025, for the supply of Ocrevus 300 mg/10 ml vials. This is a competitively awarded, firm fixed-price delivery order with no set-aside designation and an ultimate completion date of September 9, 2025. The pharmaceutical product will be delivered to AmerisourceBergen's facility in Conshohocken, Pennsylvania, where the company maintains its corporate headquarters as a major...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 12, 2025, for the supply of Ocrevus 300 mg/10 mL vials, a pharmaceutical product used to treat multiple sclerosis. This firm fixed-price delivery order, valued at $64,452.33, is scheduled for completion by September 3, 2025, with performance at AmerisourceBergen's Conshohocken, Pennsylvania facility. The contract was awarded without a set-aside designation through competitive procurement, reflecting...
- AmerisourceBergen Drug Corp was awarded a delivery order on August 4, 2025, by the Defense Logistics Agency Medical Supply Chain for the supply of Ocrevus 300 mg/10 mL vials. The contract is valued at $120,192.80 under a firm fixed-price arrangement with an ultimate completion date of August 25, 2025. This non-competitive delivery order was issued as a child contract against a larger vehicle, leveraging AmerisourceBergen's established relationship with federal medical procurement. The place of...
- SPE2DB20D1100Indefinite Delivery Contract
- SPE2DB20D1100-SPE2DB25FE2K5Delivery Order
The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 22, 2025, for the supply of Ocrevus 300 mg/10 mL vials with a ceiling value of $72,115.74. This is a firm fixed-price delivery order with an ultimate completion date of September 15, 2025, and represents a non-set-aside competitive award. AmerisourceBergen Drug Corp will perform this work at its corporate office location in Conshohocken, Pennsylvania. Ocrevus is a specialty pharmaceutical product used in the treatment of multiple sclerosis, reflecting the Defense Logistics Agency's ongoing procurement of specialized medical supplies for military and veteran healthcare systems. This delivery order is issued under AmerisourceBergen Drug Corp's existing Indefinite Delivery Contract (SPE2DX) with DLA Troop Support Medical, a comprehensive global pharmaceutical support vehicle valued at $999,999,999.00 and extending through December 2026. As the prime contractor on this IDC, AmerisourceBergen Drug Corp leverages this master contract to fulfill individual delivery orders for pharmaceutical products across multiple therapeutic domains for the Defense Health Agency, U.S. Coast Guard, and other federal healthcare customers. The company's position as a major pharmaceutical distributor and healthcare solutions provider enables it to meet the Defense Logistics Agency's specialized medical supply requirements through competitive, firm fixed-price arrangements.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $72.1k | 8/22/25 |